Literature DB >> 10999505

Once-daily aminoglycoside in the treatment of Enterococcus faecalis endocarditis: case report and review.

V H Tam1, P S Mckinnon, D P Levine, S M Brandel, M J Rybak.   

Abstract

Once-daily administration of aminoglycosides (ODA) is effective and safe for many indications. By optimizing pharmacodynamic principles, it enhances bactericidal activity and minimizes toxicity. Its use for the treatment of enterococcal infection is controversial, however, and results of in vitro studies and animal models of endocarditis are conflicting. To date, no case reports or clinical trials have examined its utility in human enterococcal endocarditis. A patient with right-sided endocarditis caused by Enterococcus faecalis was managed by once-daily gentamicin. Clinical and bacteriologic cures of this patient raise questions as to whether enterococcal endocarditis should be regarded as contraindication to ODA. The clinical utility of ODA in this disease deserves further investigation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10999505     DOI: 10.1592/phco.20.13.1116.35029

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  4 in total

1.  Simulation of human gentamicin pharmacokinetics in an experimental Enterococcus faecalis endocarditis model.

Authors:  Laurent Dubé; Jocelyne Caillon; Christèle Gras-Le Guen; Cédric Jacqueline; Marie-France Kergueris; Jean-Claude Granry; Gilles Potel; Denis Bugnon
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

2.  Section 3: Prevention and Treatment of AKI.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-03

3.  Different aminoglycoside-resistant phenotypes in a rabbit Staphylococcus aureus endocarditis infection model.

Authors:  N Asseray; J Caillon; N Roux; C Jacqueline; R Bismuth; M F Kergueris; G Potel; D Bugnon
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

4.  Gentamicin-mediated ototoxicity and nephrotoxicity: A clinical trial study.

Authors:  Parviz Saleh; Shamsi Abbasalizadeh; Saman Rezaeian; Mohammad Naghavi-Behzad; Reza Piri; Hojjat Hossein Pourfeizi
Journal:  Niger Med J       Date:  2016 Nov-Dec
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.